Larotrectinib has been launched in China and is suitable for solid tumor patients with NTRK gene fusion positivity. When using it, attention should be paid to the authenticity and production date of the drug to avoid purchasing fake or inferior drugs.

1. Listing status

(1) Larotinib has been approved for sale in China under the trade name "Vitrakvi".

(2) The drug was approved by the National Medical Products Administration in April 2022, becoming the first targeted drug for NTRK gene fusion in China.

2 Indications

(1) Used to treat adult and pediatric solid tumor patients with NTRK gene fusion positivity.

(2) Covering multiple types of tumors, including lung cancer, thyroid cancer, sarcoma, etc.

3 Purchase precautions

(1) It is necessary to purchase through formal medical institutions or pharmacies to ensure the reliability of drug sources.

(2) Check the integrity of drug packaging, approval number, and production date to avoid using expired products.